Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 5Ca.3O4P.HO |
| Molecular Weight | 502.311 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[Ca++].[Ca++].[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O
InChI
InChIKey=XYJRXVWERLGGKC-UHFFFAOYSA-D
InChI=1S/5Ca.3H3O4P.H2O/c;;;;;3*1-5(2,3)4;/h;;;;;3*(H3,1,2,3,4);1H2/q5*+2;;;;/p-10
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) ā Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015-09-16 |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014-07 |
|
| Effect of calcium phosphate and vitamin Dā supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014-01-17 |
|
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans. | 2012-04 |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009-07-02 |
|
| Henri Moissan: winner of the Nobel Prize for Chemistry 1906. | 2006-10-20 |
|
| [Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006-10 |
|
| Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003-01 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002-12 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002-11-04 |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002-09-15 |
|
| Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002-09-06 |
|
| A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002-09-06 |
|
| Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002-09 |
|
| Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002-07-05 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002-07 |
|
| Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002-07 |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002-06-15 |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002-06 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002-05-15 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002-04-19 |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002-03-15 |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002-03 |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002-03 |
|
| Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002-02-01 |
|
| CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002-02 |
|
| Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002-02 |
|
| Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002-01-15 |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001-12-21 |
|
| Complement activation in factor D-deficient mice. | 2001-12-04 |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001-11-30 |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001-11-01 |
|
| Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001-11 |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001-11 |
|
| Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001-11 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001-10-26 |
|
| Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001-10-12 |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001-10-01 |
|
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001-10 |
|
| Familial intrahepatic cholestasis 1: studies of localization and function. | 2001-10 |
|
| A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein. | 2001-09-15 |
|
| Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001-09-07 |
|
| Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. | 2001-09-01 |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001-09 |
|
| Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. | 2001-09 |
|
| Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. | 2001-08-28 |
|
| Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001-08 |
|
| [Acute renal failure caused by hypercalcemia]. | 2001-06-10 |
|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975-06 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
81622-3
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
||
|
LOINC |
87480-0
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2218916
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106566
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
1306-06-5
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
215-145-7
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
SUB01847MIG
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
TRIBASIC CALCIUM PHOSPHATE
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | Description: A white, amorphous powder; odourless or almost odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS and nitric acid (~130 g/l) TS. Category: Tablet diluent. Storage: Calcium phosphate should be kept in a well-closed container. Additional information: At relative humidities between 15% and 65%, the equilibrium moisture content at 25 ?C is about 2%, but at relative humidities above 75% small additional amounts of moisture are absorbed. Definition: Calcium phosphate is a mixture consisting mainly of Ca3(PO4)2 together with CaHPO4. Calcium phosphate contains not less than 34.0% and not more than the equivalent of 40.0% of calcium, Ca, calculated with reference to the ignited substance. | ||
|
C45678
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
91D9GV0Z28
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
m4784
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
5804
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
100000138411
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
Calcium hydroxyphosphate
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
SUB34727
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
52254
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
SUB77913
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
D017886
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
DBSALT002431
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
235-330-6
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
1087031
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
SUB13191MIG
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
C84224
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
91D9GV0Z28
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
14781
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
9679
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | |||
|
49334
Created by
admin on Mon Mar 31 18:13:48 GMT 2025 , Edited by admin on Mon Mar 31 18:13:48 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY
